# Open-label Extension Study of Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Lupus Nephritis

> **NCT05232864** · PHASE3 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 31 (actual)

## Conditions studied

- Lupus Nephritis

## Interventions

- **DRUG:** Secukinumab

## Key facts

- **NCT ID:** NCT05232864
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-08-22
- **Primary completion:** 2023-08-23
- **Final completion:** 2023-08-23
- **Target enrollment:** 31 (ACTUAL)
- **Why stopped:** Study terminated by sponsor based on a futility analysis of the core study CAIN457Q12301
- **Last updated:** 2025-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05232864

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05232864, "Open-label Extension Study of Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Lupus Nephritis". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05232864. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*